1. Scrip
  2. >>New Products

Pfizer’s Eucrisa Approval By FDA Adds New Dermatology Anchor

 
• By Jessica Merrill

Pfizer’s Eucrisa is one of the first new drugs to launch for the treatment of atopic dermatitis in more than a decade. The launch reflects an expansion strategy by Pfizer to move into a new therapeutic area – dermatology.

Pfizer Inc. will launch Eucrisa (crisaborole) in January as the first new drug for atopic dermatitis in more than a decade and as the first prong in a strategy to expand into dermatology, a new therapeutic area for the big pharma. Pfizer announced the FDA approval of the topical non-steroidal phosphodiesterase-4 (PDE-4) inhibitor Dec. 14 for the treatment of mild-to-moderate atopic dermatitis in patients two and older.

Eucrisa is the first of several new drugs on the horizon to treat atopic dermatitis, a chronic rash that falls under the eczema umbrella but which can be severe. ([A#SC097514/]) Rivals Sanofi and Regeneron Pharmaceuticals Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Scrip

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.